Background: Approximately one-third of those with pediatric-onset multiple sclerosis (MS) experience cognitive impairment. Less is known concerning their change in cognitive functioning over time. Objective: Changes in cognitive function over time were measured in the largest pediatric cohort to date through the US Network of Pediatric MS Centers. Methods: A total of 67 individuals with pediatric MS (n=62) or clinically isolated syndrome (CIS, n=5), ranging from 8-17 years of age (mean age±standard deviation (SD)=14.37±2.02) completed initial and follow-up neuropsychological testing after an average of 1.64±0.63 years apart. The nine tests administered measure general intellect, attention and working memory, verbal memory, visuomotor integration, language, and executive functioning. Results: Rate of impairment (having one-third or more scores in the impaired range) was 37% at baseline and 33% at follow-up. Tests commonly impaired were measures of visuomotor integration, speeded processing, and attention. Most tested did not decline over two years. There was no clear pattern of change on any specific measure. Conclusion: Findings suggest that, over short timeframes, stable or even improved performances on measures of cognitive ability can occur. Pediatric MS may instead prevent expected age-related cognitive gains.
Introduction
Multiple sclerosis (MS) is an immune-mediated disorder of the central nervous system marked by demyelinating events and accumulated neurological disability. Pediatric MS refers to the onset of the disorder before the age of 18 years and represents approximately 3-5% of all MS cases. 1, 2 Across studies, cognitive impairment has been estimated to occur in approximately one-third of pediatric MS cases compared to an estimated one-half or more adult patients. Rates of cognitive impairment in pediatric MS patients are generally consistent despite variations in measures and definition of impairment, and comparison to published normative values or matched groups of healthy control participants, e.g., 35%, (n=37) 3 , 31%, (n=63) 4 , 29%, (n=31) 5 , 35%, (n=187) 6 . Areas of dysfunction most often involve include visuomotor integration, information processing, learning, and, in some studies, language. 4 Fewer studies have examined cognitive function across time. Initial reports indicated pediatric patients to be at risk for decline. For example, studies have found that some patients decline from previously normal functioning or, with prior dysfunction, experience further decline over time. 7 In a sample of 56 pediatric MS participants followed for two years and compared to two sets of matched healthy control participants recruited at each time point, Amato and colleagues 8 classified 75% of the sample with cognitive deterioration. The authors defined decline using a Cognitive Change Index (CCI), determined as a drop in two or more points in a total of scores weighted according to standard deviations from the normative means. However, in a sample of 28 pediatric MS participants compared to a matched healthy control group, all followed for one year, Till and colleagues 9 found a lower rate of decline (25% in the MS vs 4% in the control sample) based on reliable change indices (RCIs). However, MS participants showed an absence of expected age-related gains over time relative to the healthy controls.
The US Pediatric MS Network is a group of nine centers across the country, funded by the National MS Society and dedicated to clinical care and research for patients with pediatric MS. This is the first Network report on longitudinal changes in cognitive functioning from a cohort who have received serial neuropsychological evaluations.
Method
Participants underwent baseline neuropsychological testing between the ages of 8-18 years and met criteria for a diagnosis of pediatric MS or clinically isolated syndrome (CIS). 2 Participants were excluded if they had a history of head injury, were diagnosed with another neurologic or a primary psychiatric disorder, or if they had another significant medical illness that could influence cognitive function. Written consent was obtained from a parent or guardian for all participants, all of whom provided their assent for the study. Participants were not provided compensation for their time. The study was approved by each participating institution's review board.
Using a common neuropsychological protocol, all patients were evaluated consecutively at their baseline visit at each site and then routinely followed after their baseline visits with the goal for repeat cognitive evaluation 18 months later. A cognitive evaluation was only completed if the participant was free of relapse and had no steroid dose for the prior 30 days. Parents were asked to complete a demographics questionnaire in which they provided the race and ethnicity of their child. Race and ethnicity were assessed to evaluate the racial and ethnic distribution in the pediatric population in MS.
A licensed clinical neuropsychologist at each site either administered or supervised a trained psychometrician to administer the battery of cognitive tests. The test administration took approximately two hours to complete (often as part of a longer neuropsychological battery) and breaks were provided as necessary. Where possible, equivalent test forms were alternated at each administration to minimize practice effects.
A subset of tests from the common battery, narrowed to the tests that were most consistently administered across the sites, was included in the current analyses (Table 1 ). These tests yielded 12 performance scores that were then compared between baseline and follow-up evaluations, as follows: Wechsler Abbreviated Scale of Intelligence -First and Second Editions (WASI, WASI-II) 10, 11 two-subtest Full Scale Intelligence Quotient (IQ) score; California Verbal Learning Test -Child Version (CVLT-C, up to 16 years of age at time of testing) 12 or Second Edition (CVLT-II, if 17 or more years of age at time of testing) 13 scores for total trial learning and long-term delayed free recall; Expressive One-Word Picture Vocabulary Test (EOWPVT) 14 total score; Pseudoword Decoding subtest total score of the Wechsler Individual Achievement Test -Second Edition (WIAT-II); 15 Beery-Buktenica Developmental Test of Visual-Motor Integration (Beery-VMI) 16 total score; Digit Span subtest from the Wechsler Intelligence Scale for Children -Fourth Edition (WISC-IV, up to 16 years of age at time of testing) 17 or Wechsler Adult Intelligence Scale -Fourth Edition (WAIS-IV, if 17 years or more at time of testing), 18 digit forward and digit backward total scores; the Trail Making Test (TMT) from the Delis-Kaplan Executive Functioning System (DKEFS) 19 total scores for conditions of visual scanning, number sequencing, letter sequencing, number/letter switching, and motor speed.
Results
There were a total of 67 participants, 62 diagnosed with pediatric MS and five with CIS. The majority of the cohort was enrolled at the Lourie Center for Pediatric MS at Stony Brook Medicine (n=40), followed by Partners Pediatric MS Center at the Massachusetts General Hospital for Children (n=16), the Center for Pediatric-Onset Demyelinating Disease at the Children's Hospital of Alabama (n=4), University of California at San Francisco Regional Pediatric MS Center (n=4), and the Pediatric MS Center of the Jacobs Neurological Institute at State University of New York (SUNY) Buffalo (n=3). Recruitment began in 2005; the final follow-up visit was completed in April 2013.
Demographics
Baseline characteristics are provided in Table 2 . Race was not available for two participants. Seventy-two percent (n=48) of the cohort were white and 31% (n=21) were of Hispanic ethnicity. Parent education (average of parent total years of education) was an average of 13.85±2.18 years, and ranged from 7.5-18 years. Time between baseline and follow-up testing was 1.64±0.63 years with a range of 0.75-3.38 years.
Clinical features
At the baseline neuropsychological visit, mean age at symptom onset was 12.94±3.13 years with a range of 3.15-16.81 years. Mean duration from symptom onset at first visit was 1.56±1.93 years with a range of 0.09-9.27 years. The median Expanded Disability Status Scale (EDSS) 20 score was 1.25 with a range of 0-3.5 at the baseline visit. At the return visit for follow-up neuropsychological testing, the median EDSS score was 1.00 with a range of 0-4.5.
Cognitive functioning
Baseline and follow-up raw scores were initially transformed to z scores using published age-normative data, and averaged for each participant to provide an overall summary score to serve as an index of cognitive functioning. Across all analyses, cognitive impairment on a test was defined as a score falling one standard deviation or more below published normative means.
As a whole, the cohort functioned within the average range at both baseline and follow-up. At baseline, the mean summary score was z=−0.23±0.74, with a range of −1.97−1.88. At follow-up, the mean summary score was z=−0.21±0.59, with a range of −1.52−0.69. The group mean percentage of impaired test scores was 25.2% (median 23.1%, range 0 to 83%) at baseline and 24.9% (median 16.7%, range 0-69%) at follow-up. The overall percent of patients with cognitive impairment, defined as having onethird or more test scores in the impaired range, was 37.3% at baseline and 32.3% at follow-up.
While the mean of summary z-scores was within the average range, consistent with prior findings, the lowest performances for the group were for visuomotor integration (Beery-VMI), verbal recall (CVLT delayed recall), and attention (Digit Span). Table 3 shows the mean z-scores for each measure at baseline and follow-up.
Demographic-adjusted impairment rates Following the method described by Smerbeck and colleagues, 21, 22 regres sion-based z-scores were calculated to adjust for demographic factors of age, gender, race, and years of parent education for a subset of the cohort with complete scores and demographic data (n=40). These regression formulas used normative data from the SUNY Buffalo site provided by locally-recruited healthy control participants (n=102), with normative data available for six of the 12 scores in this analysis: WASI Full Scale IQ, CVLT-C/II total trial learning and long delay free recall, and total scores from EOWPVT, Beery-VMI, and Pseudoword Decoding. Measured by adjusted z-scores, the mean summary scores were slightly higher while remaining within the average range. At baseline, the mean±SD z= −0.16±0.83, with a range of -2.69−1.67. At followup, the mean±SD z= −0.07±0 .80, with a range of −2.20−1.39. Using these regression-based norms, the mean impaired test performance rate was generally consistent with that found using published normative data, 24.6% (vs 25.2%) at baseline and 21.0% (vs 24.9%) at follow-up. However, there was an overall higher percent of impairment, defined as having one-third or more test scores in the impaired range, of 40.0% (vs 37.3%) at baseline and 37.5% (vs 32.3%) at follow-up. These findings are consistent with the previous demonstration of improved sensitivity with the regression-based normative data for detecting impairment on certain tests. 21, 22 Table 4 shows the adjusted mean z scores at baseline and follow-up.
Change in cognitive functioning over time
The mean change in summary score was z=0.02±0.45, with a range of −0.22−1.05, indicating variability in both directions with no significant change on average. As shown in Figure 1 , paired sample t-tests indicated no significant changes in mean z-scores on any individual test (Bonferroni corrected p<0.001).
There were also no significant changes using the adjusted z-scores (Bonferroni corrected p<0.01), although scores for the CVLT-C/II (total trial learning and delay) and Pseudoword Decoding trended towards significant improvement (p=0.04, 0.02, and 0.05, respectively).
To determine individual change in impairment over time, the difference in the sum of impaired test measures at baseline and follow-up was calculated. The group's overall change was minimal with a mean sum of −0.15±1.48 impaired measures and ranged from −4.00−5.00. There was an approximately equal distribution of improvement and decline (Figure 2 ). Most participants showed no change while n=4 (6%) declined on two or more tasks and n=6 (9%) improved on two or more tasks. This analysis was repeated using the CCI 8 which assigns each score a weight indicating its categorical distance from the published normative mean (a weight of "1" is assigned to z-scores falling between 0 and −1, a weight of "2" is assigned to a score below −1 and above −2, etc.). This method provides the advantage of categorizing change only if the score moves to a different standard deviation range (e.g. from 0 to −1 to −1 to −2). The mean CCI at baseline was 11.37±6.72 and 10.85±6.03 at follow-up, with a mean change in CCI indicating slight improvement, −0.52±4.12.
There was no pattern of decline or improvement on any test, or in any functional area. A logistic regression was performed to assess the influence of clinical and demographic characteristics predicting decline on one or more tasks at follow-up, and included age, gender, race, parent education, and EDSS. Decline at follow-up was not significantly predicted by any clinical or demographic features. The full model did not show any influence of these covariates χ 2 (4, N=44) = 2.99, p=0.56, explaining only 6-9% of the variance in those who declined versus remained stable or improved. As follows, none of the predictors approached significant contribution to the prediction of classification (all p values>0.22). In sum, decline at follow-up was not significantly predicted by any clinical or demographic features.
RCIs
RCIs were calculated for each raw score based on the Jacobson and Truax 23 formula
with x1 representing the baseline score, x2 the follow-up score, and SDiff the standard error of the difference, calculated using test-retest reliability coefficients for each test. The RCIs may serve to mitigate any practice effects from repeat administration of the tests and provide a metric of more clinically meaningful change. Change was considered significant (in either direction) using the cut point of 1.96, which corresponds to the significance level of p<0.05. 23 In sum, six (9%) participants improved on one score and three (4.5%) significantly declined on one score. The measures showing decline were the DKEFS TMT conditions of visual scanning (n=1) and number sequence (n=1), and the CVLT total learning score (n=1). Improvements also included the DKEFS TMT condition of visual scanning (n=2), as well as letter sequencing (n=1), letter/ number switching (n=2), and the CVLT delay score (n=1). No one participant consistently improved or declined on more than one score, and, as with the other analytic approaches, there was no consistent pattern of improvement or decline.
Discussion
Taken together, the current findings indicate that cognitive impairment remains relatively stable in pediatric MS over a mean interval of 1.65 years. Frequency of cognitive impairment in this cohort was consistent with previous reports, involving the expected areas of visuomotor integration, learning and information processing. The finding of relative stability over time was consistent across a range of analytic approaches for measuring change including comparisons at the group and individual level, using both published and demographically-adjusted regression-based normative data, as well as with CCI weighted scores and RCIs.
Whereas cognitive stability can be found over similar intervals in adult MS, [24] [25] [26] [27] these findings differ from the initial reports of significant decline in pediatric MS. 8, 9 In the largest previous cohort, an Italian sample, Amato and colleagues reported a 75% rate of decline in an Italian sample across an average of two years. 8 It may be that the duration of this study, an average of 1.65 years, is not adequate to determine cognitive impairment. However, the current cohort also differed from the Italian sample in the nature and severity of baseline deficits. For example, there was more intellectual impairment in the Amato. et al. 8 cohort (28%) while only one participant in the current cohort had an IQ of less than 85.
In addition, the battery used by the Italian group both included more measures of language function than in the current study and found more language problems. While fewer language measures were included, the current findings did not indicate language impairment or decline. Instead, the scores derived from the regression-based normative data showed a trend towards significant improvement in two of the language-based measures (CVLT and Pseudoword Decoding). The Italian cohort also had a younger age of symptom onset (11.7 years versus 12.9 years in this cohort) with earlier onset linked to greater risk of cognitive decline, similar to an earlier report by Banwell and Anderson. 28 We did not find that age of symptom onset was linked to either cognitive impairment or risk of decline. However, this cohort included relatively few of these youngest onset patients (n=8 or 11.9% with onset under the age of 10 years). Other clinical features may also explain the discrepant findings; unfortunately, additional clinical data were not available to include for analysis.
Instead, our findings of lower levels of decline are consistent with the results reported by Till and colleagues in a Canadian sample. 9 Theirs is the only study to date to include a longitudinal control group followed over time and suggests that MS occurring in the context of development may exact its greatest cost by inhibiting age-expected gains.
A major limitation to the current study is the absence of a matched control group to compare cognitive changes over time. Analyses from the regressionbased normative data suggest that this would be a preferred and more sensitive method for detecting impairment versus reliance on published normative data. A locally-recruited and matched control group would minimize the influence of regional and other demographic factors. Most importantly, a parallel group recruited and followed over time is the best approach to determine any meaningful change in cognitive functioning attributable to pediatric MS. However, even in the absence of a control comparison, our analytic approaches have clearly indicated that there was no pattern of decline in this sample.
Another limitation of the current study is the relatively few clinical descriptors of disease status that were available to relate to the neuropsychological findings. For instance, with the limited data available on the use of disease-modifying treatments (DMTs) in this study, it was not possible to accurately examine this potential clinical predictor. However, both the Italian and Canadian longitudinal studies reported similarly high rates of DMT use for their samples (88% and 81%, respectively) but differed in findings of cognitive decline. More importantly, the focus of this research was not directed towards the role of DMT on cognitive performance. To accurately answer the role of DMTs in prevention of cognitive decline, a prospective design with the collection of detailed DMT use should be used. Additional clinical information, including detailed measurement of disease activity through clinical relapses and brain magnetic resonance imaging would provide a more specific indicator of disease activity and severity. Nonetheless, with the general absence of decline in our sample, we would not have had adequate power to evaluate these clinical predictors of cognitive change.
The study was also limited by the measures of cognitive functioning included for analyses. While we administered measures that were representative of a general clinical battery, the inclusion of additional measures would have provided a richer assessment of functioning at the individual level. Specifically, the inclusion of additional tests of language functioning would have facilitated comparison to the Italian sample with its findings of language impairment. Finally, the interpretation of neuropsychological data with respect to real life impact is limited in the absence of functional outcomes. For instance, future studies might include measures of school performance and parent report as well.
Despite these limitations, we report on the largest longitudinally studied sample to date and the first longitudinal study of cognition with a multicenter US population. The finding of relatively stable cognitive functioning in this cohort adds to the evolving picture of cognitive impairment in pediatric MS.
